EX-10.1610-Q·CIK 1795851·0001795851-26-000016

Lauderhill, Florida 33351

View original filing on SEC EDGAR → ·  seen Nov 16, 2026, 16:28 EST

CONFIDENTIAL – CONTAINS MATERIAL NON-PUBLIC INFORMATION – DELIVERED UNDER SECTION 4(p) OF THE SPA PURSUANT TO THE BUYER’S CONSENT DATED NOVEMBER 10, 2026

STEWARDS, INC.

4300 N. University Drive, Suite D-105

Lauderhill, Florida 33351

November 16, 2026

Crom Structured Opportunities Fund I, LP

228 Park Avenue South, PMB 57033

New York, NY 10003

Attention: Liam Sherif

Email: notices@crom-llc.com; john@crom-llc.com; liam@crom-llc.com

Re: Request for Consent, Waiver and Acknowledgment – Securities Purchase Agreement dated October 28, 2026

Ladies and Gentlemen:

Reference is made to the Securities Purchase Agreement dated October 28, 2026 (the “SPA”) between Stewards, Inc. (the “Company”) and Crom Structured Opportunities Fund I, LP (the “Buyer”), and the Unsecured Convertible Promissory Note issued thereunder on October 28, 2026 (together with any other Offering Notes, the “Note”). Capitalized terms used but not defined herein have the meanings given to them in the SPA or the Note, as applicable.

1. Background.

(a) 15% Notes.The Company has outstanding fifteen percent (15%) secured promissory notes with an aggregate face value of $31.829 million, as set forth in the Company Information Schedule (the “15% Notes”). Under Amendment No. 1 to 2024 Secured Promissory Notes, effective March 17, 2026 and entered into with holders representing a Majority in Interest (“Amendment No. 1”), the maturity of the 15% Notes issued under the note purchase agreements dated on or about June 14, 2024 was extended to March 17, 2028, with automatic one-year renewals thereafter unless a holder timely delivers a notice of non-renewal.

(b) Interest Status, Waiver and Deferral.Interest on the 15% Notes has been paid through August 31, 2026. The Company has requested that the holders of the 15% Notes waive in writing any default arising from the timing of interest payments and agree to a standstill with respect to unpaid interest through January 31, 2027 (the “15% Notes Waiver”), and enter into an Interest Deferral Agreement with the Company (the “Interest Deferral Agreement”) providing for the issuance of the Interest Notes described in Section 2(a).

(c) FAVO Note.The final installment of $1.6 million under the Company’s promissory note payable to FAVO Holdings, LLC (the “FAVO Note”), a related party owned in part by the Company’s Chief Executive Officer, matured on October 15, 2026. Under Amendment No. 3 to the FAVO Note dated as of October 15, 2026 and executed November 11, 2026 (“FAVO Amendment No. 3”), the maturity of the final installment was extended to January 15, 2027.

Crom Consent, Waiver and Acknowledgment – Page 1


(d) Envy Transactions.The Company did not make the $3,000,000 monthly Required Redemptions due October 5 and November 5, 2026 under the Membership Interests Purchase and Sale Agreement dated as of September 21, 2026 (the “Envy MIPA”), and did not repay at its original maturity of October 5, 2026 the $2,000,000 promissory note issued to Envy Development PB, LLC with an effective date of September 17, 2026 (the “Envy Seller Note”). As of November 13, 2026, the Company and the sellers under the Envy MIPA (the “Envy Sellers”) have executed, and placed in escrow pending the Buyer’s consent under this letter, agreements providing for (i) the First Amendment to the Envy MIPA (the “Envy Amendment”), under which the 7,000,000 Escrowed Shares are exchanged for 7,000,000 shares of the Company’s Series D Convertible Preferred Stock, with a stated value of $3.00 per share and convertible into Common Stock on a one-for-one basis (the “Series D Preferred”), in full satisfaction of the $21.0 million consideration obligation, and the Required Redemptions are terminated; (ii) an unsecured promissory note in the principal amount of $1,364,000, payable in five monthly installments through April 5, 2027 (the “Late Payment Note”) in full satisfaction of the late payment damages under the Envy MIPA and the late charge on the Envy Seller Note; (iii) an Extension Agreement and First Amendment to Promissory Note, effective as of October 5, 2026, extending the maturity of the Envy Seller Note to November 30, 2026 (the “Envy Extension”); and (iv) the related amendments to the registration rights agreement and escrow agreement entered into under the Envy MIPA (together with the Envy Amendment, the Late Payment Note and the Envy Extension, the “Envy Transactions”). The Envy Amendment also provides for a review every three months of the $3.00 minimum sale price under its leak-out provisions, after which the Company’s independent directors may, in their discretion, reduce that minimum, subject to Section 2(g); the daily volume limitation is unchanged.

(e) Offshore Facility.The Company is party to the Loan Agreement dated September 17, 2025 with Stewards International Funds PCC (on behalf of the Stewards Private Credit Fund), as amended (the “Offshore Facility”) and on August 13, 2026 received a written commitment from Stewards (International) Limited, acting as CIS manager of Stewards International Funds PCC for its Stewards Private Credit Fund, to provide the Company with at least $24.0 million of funding over the following twelve months through existing and new debt-financing arrangements (the “Offshore Commitment”).

(f) Deposit Notes.The Company holds four promissory notes issued by PIXL Development, LLC (one of them also by The Myelin Group, LLC) evidencing deposits and reimbursable costs advanced by the Company in connection with the PIXL Acquisition (as defined in the SPA), in the aggregate original principal amount of $1,080,000 (the “PIXL Deposit Notes”). By First Addenda executed on or after October 28, 2026, the Company and the makers extended the maturity of the PIXL Deposit Notes to the earlier of the closing of the PIXL Acquisition and November 30, 2026, providing that at that closing the principal of the deposit notes will be credited against the purchase price and the $200,000 reimbursement note will be cancelled. By First Addenda executed on November 10, 2026, the Company, The Myelin Group, LLC and Envy Development DE, LLC confirmed that four promissory notes held by the Company in the aggregate original principal amount of $1,600,000 (the “Envy Deposit Notes” and, together with the PIXL Deposit Notes, the “Deposit Notes”) were credited against the purchase price or cancelled at the closing under the Envy MIPA on September 23, 2026.

Crom Consent, Waiver and Acknowledgment – Page 2


2. Consents Requested.The Company requests the Buyer’s written consent to the following (collectively, the “Transactions”):

(a) Interest Notes.The Company’s entry into an Interest Deferral Agreement with the holders of the 15% Notes, and its issuance of subordinated interest notes thereunder in the aggregate principal amount of $6,340,840, substantially in the forms attached hereto as Annex A (the “Interest Notes”). The Interest Notes are unsecured, non-convertible and subordinated in right of payment to the Offering Notes, and represent interest on the 15% Notes for the period from September 1, 2026 through December 31, 2027. At the request of the holders, Section 4A of the Interest Deferral Agreement sets the order in which the Company’s payments on the 15% Notes and the Interest Notes are allocated among the holders, without changing the amount or timing of any payment by the Company or the subordination of the Interest Notes. For such purpose, the Buyer:

(i) consents, pursuant to Section 4(w) of the SPA, to the 15% Notes Waiver and the limited amendment of the 15% Notes set forth in the Interest Deferral Agreement, and acknowledges that Amendment No. 1 was entered into and became effective before the date of the SPA and did not require the Buyer’s consent under Section 4(w) of the SPA;

(ii) agrees that the Interest Notes constitute Permitted Indebtedness under Section 2.2(e) of the Note;

(iii) consents, pursuant to Section 2.4 of the Note, to payments on the Interest Notes at or prior to maturity, to the extent permitted by their subordination terms;

(iv) waives its rights under Section 4(d) of the SPA with respect to the Interest Notes; and

(v) to the extent the issuance of the Interest Notes may be deemed a 3(a)(9) Transaction, consents thereto pursuant to Section 2.7 of the Note, and agrees that no liquidated damages shall be assessed in connection therewith.

(b) FAVO Note.Pursuant to Section 4(w) of the SPA and Section 2.6 of the Note, the Buyer ratifies and consents to FAVO Amendment No. 3, including the extension of the maturity of the final installment of the FAVO Note to January 15, 2027 with interest at a rate not to exceed ten percent (10%) per annum, and the Company agrees that it will make no payment of principal of or interest on the FAVO Note until the Offering Notes have been converted or repaid in full. Before January 15, 2027, the Company shall enter into an amendment to the FAVO Note (“FAVO Amendment No. 4”) extending its maturity to a date after the maturity date of the Offering Notes and subordinating it in right of payment to the Offering Notes until they have been converted or repaid in full, on terms reasonably acceptable to the Buyer, and the Buyer consents to FAVO Amendment No. 4 on those terms.

(c) Envy Transactions.The Buyer:

(i) consents, pursuant to Section 2.7 of the Note, to the exchange of the Escrowed Shares for the Series D Preferred and to the issuance of Common Stock upon conversion of the Series D Preferred, in each case to the extent structured as or deemed to be a 3(a)(9) Transaction, and agrees that no liquidated damages or other amounts shall be assessed under Section 2.7 of the Note in connection

Crom Consent, Waiver and Acknowledgment – Page 3


therewith, and, pursuant to Sections 2.3 and 2.4 of the Note, consents to the acquisition and cancellation of the Escrowed Shares in that exchange; the Buyer does not consent to any redemption of the Series D Preferred while any Offering Note remains outstanding, and the Company agrees not to redeem any Series D Preferred during that period, which agreement is not a condition to the effectiveness of the Envy Amendment;

(ii) consents, to the extent required by Section 4(w) of the SPA and Section 2.6 of the Note, to the Envy Transactions, including the Envy Extension;

(iii) agrees that the Late Payment Note constitutes Permitted Indebtedness under Section 2.2(e) of the Note;

(iv) consents, pursuant to Sections 2.4 and 2.6 of the Note, to the Company’s payment of the principal of and interest on the Late Payment Note and the Envy Seller Note in accordance with their terms, as amended by the Envy Transactions;

(v) waives its rights under Sections 4(d), 4(n) and 4(u) of the SPA with respect to the Series D Preferred and the Late Payment Note;

(vi) to the extent any Envy Seller or any principal of an Envy Seller is deemed an affiliate of the Company, consents, pursuant to Section 2.6 of the Note, to the payment of the Guaranty Fee under Section 2.2.3(c) of the Envy MIPA in cash in accordance with its terms, and the Company agrees that no portion of the Guaranty Fee will be paid in shares of Common Stock; and

(vii) consents, pursuant to Sections 2(c), 11(k) and 11(l) of the Registration Rights Agreement dated October 28, 2026 between the Company and the Buyer (the “Crom RRA”), to (A) the amendment of the registration rights agreement entered into under the Envy MIPA described in Section 1(d)(iv), which requires the Company to register for resale the Common Stock held by the Envy Sellers or issuable upon conversion of the Series D Preferred (the “Envy Shares”), and agrees that such amendment does not impair or conflict with the Buyer’s rights under the Crom RRA, and (B) the registration for resale of (1) the Envy Shares and (2) any shares of Common Stock issued or issuable as consideration in the PIXL Acquisition (as defined in the SPA) that the Company is required to register for resale (the “PIXL Shares”) on a separate registration statement filed after the Registration Statement filed under the Crom RRA has been declared effective. The filing and effectiveness deadlines and the remedies under the Crom RRA are not affected.

(d) Offshore Facility.The Buyer acknowledges and agrees that (i) borrowings under the Offshore Facility and the Offshore Commitment, any renewal, extension, amendment, refinancing or replacement of the Offshore Facility (including beyond November 15, 2026), and payments of principal of and interest on the Offshore Facility (including interest of $452,000 payable on September 1, 2026) are Offshore Facility Transactions and Exempt Transactions under Section 4(v) of the SPA and, subject to Section 2(f), do not require the Buyer’s consent under the Transaction Documents, other than Section 4(o) of the SPA, and (ii) to the extent the issuance of warrants to the lender under the Offshore Facility in connection with borrowings under the Offshore Facility or the Offshore Commitment, on the terms of the Offshore Facility as in effect on the date of this letter (including the anti-dilution adjustment in Section 4.2 of the related warrant agreement),

Crom Consent, Waiver and Acknowledgment – Page 4


constitutes a Variable Rate Transaction, the Buyer consents to it pursuant to Section 4(o) of the SPA.

(e) Deposit Notes.To the extent required by Section 2.6 of the Note, the Buyer consents to the First Addenda to the Deposit Notes, including the extension of the PIXL Deposit Notes, the crediting of their principal against the purchase price for the PIXL Acquisition and the cancellation of the $200,000 reimbursement note at its closing.

(f) Conditions to Certain Payments.The Buyer’s consents to payments to the lender under the Offshore Facility under Section 2(d) and in respect of the Guaranty Fee under Section 2(c)(vi) are subject to the conditions that (i) no such payment is made from the proceeds of the Offering Notes, consistent with Section 4(c) of the SPA, and (ii) no such payment is made while an Event of Default under the Offering Notes is continuing.

(g) Envy Leak-Out.So long as any Offering Note remains outstanding, the Company shall not waive, reduce or otherwise modify the Minimum Sale Price or the daily selling limitation under Section 3.6 of the Envy Amendment (including under the quarterly review provided for in Section 3.6(c) of the Envy Amendment) without the Buyer’s prior written consent.

3. Confirmation and Waiver.The Buyer confirms that the entry into and consummation of the Transactions in accordance with their terms, in the forms attached as Annex A, do not and will not constitute or give rise to an Event of Default or a breach of the SPA, the Note or any other Transaction Document. This confirmation does not extend to any failure by the Company after the date of this letter to pay or perform when due under any instrument entered into or amended in the Transactions, including the Envy Seller Note at its extended maturity of November 30, 2026, the Late Payment Note, the Interest Notes and the FAVO Note. The Buyer further waives any Event of Default under Sections 3.3, 3.4 or 3.14 of the Note that has arisen or may be deemed to have arisen from (a) the timing of interest payments on the 15% Notes prior to the 15% Notes Waiver; (b) the maturity of the FAVO Note on October 15, 2026 without payment; (c) the non-payment of the Required Redemptions and the accrual of late payment damages under the Envy MIPA, and the non-payment of the Envy Seller Note at its original maturity, in each case prior to the effectiveness of the Envy Transactions; or (d) the non-payment of interest due September 1, 2026 under the Offshore Facility, and waives any breach of Sections 3(g) or 3(gg) of the SPA arising solely from the extent to which the Company Information Schedule did not reflect Amendment No. 1. The Scheduled Default provisions of Section 3(gg) of the SPA continue to apply. The Buyer further confirms that none of the following, on the terms set forth in the documents attached as Annex A as of the date of this letter, triggers any adjustment under Section 1.6(e) of the Note or any rights under Section 4(n) of the SPA: (i) the Interest Notes; (ii) the Late Payment Note; (iii) the issuance of the Series D Preferred in exchange for the Escrowed Shares; and (iv) the conversion of the Series D Preferred at the Conversion Rate set forth in the Certificate of Designation of the Series D Preferred, as adjusted only for stock splits, combinations, stock dividends and reclassifications. This confirmation does not extend to (A) any shares issued in payment of the Guaranty Fee or any other fee or payment shares, (B) any securities issued in connection with the PIXL Acquisition, (C) any amendment of those instruments after the date of this letter or (D) any other issuance.

4. Limited Effect.This consent is limited to the Transactions described herein and does not extend to any other transaction, including any sale, restructuring or exchange of the 15% Notes into equity or convertible securities or any 3(a)(10) Transaction. Except as expressly set

Crom Consent, Waiver and Acknowledgment – Page 5


forth herein, the SPA, the Note and the other Transaction Documents remain unchanged and in full force and effect.

5. Confidential Information.This letter and its Annex A are the Information delivered under Section 4(p) of the SPA pursuant to the Buyer’s email to the Company dated November 10, 2026 (the “Section 4(p) Consent”), and are subject to the Buyer’s confidentiality obligations under the Section 4(p) Consent. The Company agrees to publicly disclose all material non-public information included in this letter and its Annex A, including this letter as executed and the Transactions, no later than 5:30 p.m., New York City time, on November 16, 2026, in its Quarterly Report on Form 10-Q for the quarter ended September 30, 2026 or in a Current Report on Form 8-K. Any failure to do so is a breach of Section 4(p) of the SPA, to which no cure period under Section 3.3 or Section 3.16 of the Note applies, and, in that event, the Buyer’s confidentiality obligations under the Section 4(p) Consent shall terminate as of such time and the Buyer may publicly disclose such information.

6. Prior Written Consent; Effectiveness.This letter is effective upon the Buyer’s countersignature. The Buyer’s consent under Section 2.7 of the Note is given before, and constitutes the Buyer’s prior written consent to, the closing of the Envy Amendment, and the Company may rely on it in closing the Envy Transactions. If the Amendment Effective Date under the Envy Amendment does not occur by the Outside Date (as defined therein), or the 15% Notes Waiver and the Interest Deferral Agreement are not executed by the holders of all of the 15% Notes by December 31, 2026, the waivers in clauses (a) and (c) of Section 3, as applicable, shall apply only to events occurring on or before the date of this letter, and the Buyer’s consents in Sections 2(a) and 2(c), as applicable, shall be of no further effect.

7. Miscellaneous.This letter shall be governed by the law governing the SPA. This letter may be executed in counterparts and by electronic signature, each of which shall be deemed an original. The Buyer’s consent extends only to the documents in the forms attached as Annex A, as corrected for typographical, clerical or conforming errors that do not adversely affect the Buyer and do not change any price, conversion rate, stated value, share number, principal amount, interest rate or payment term.

Crom Consent, Waiver and Acknowledgment – Page 6


Please indicate the Buyer’s consent to the foregoing by countersigning this letter where indicated below.

Very truly yours,

STEWARDS, INC.

By: /s/ Shaun Quin

Name: Shaun Quin

Title: President and Chief Executive Officer

CONSENTED AND AGREED:

CROM STRUCTURED OPPORTUNITIES FUND I, LP

By: CROM STRUCTURED OPPORTUNITIES FUND I GP, LLC, its General Partner

By: CROM CORTANA FUND LLC, member of the General Partner

By: /s/ Liam Sherif

Name: Liam Sherif

Title: Authorized Signatory

Date:

Crom Consent, Waiver and Acknowledgment – Page 7


ANNEX A

INTEREST DEFERRAL AGREEMENT, SUBORDINATED INTEREST NOTE AND 15% NOTES WAIVER (FORMS); ENVY AMENDMENT, SERIES D CERTIFICATE OF DESIGNATION, LATE PAYMENT NOTE (FORM) AND ENVY EXTENSION; DEPOSIT NOTE ADDENDA

A-1 15% Notes Waiver Letter (form dated November 12, 2026)

A-2 Interest Deferral Agreement, with Schedule A and Exhibit A (form dated November 12, 2026, including Section 4A)

A-3 Subordinated Interest Notes (form, as revised November 12, 2026)

A-4 First Amendment to the Envy MIPA, dated as of November 13, 2026 (executed, held in escrow), including Exhibit E (Certificate of Designation of Series D Convertible Preferred Stock)

A-5 Late Payment Note, dated November 10, 2026, $1,364,000, the references in which to the First Amendment are to the Envy Amendment dated as of November 13, 2026 (executed by the Company and the Envy Sellers and held in escrow)

A-6 Envy Extension (executed, held in escrow)

A-7 First Addenda to the Deposit Notes (executed)

A-8 First Amendment to the Envy Registration Rights Agreement, dated as of November 13, 2026 (executed, held in escrow)

A-9 FAVO Amendment No. 3 (executed)

Crom Consent, Waiver and Acknowledgment – Page 8

Back to all agreements